Zydus Lifesciences Limited — Updates, 12-02-2025: Press Release

Zydus Lifesciences Ltd. has signed an exclusive development, licensing, supply, and commercialization agreement with Synthon BV for a novel 505(B)(2) oncology product aimed at the US market. Synthon will handle the development and manufacturing, while Zydus will take charge of the NDA submission and commercialization. The product is expected to be filed in 2026, targeting enhancements in patient compliance through reduced pill burden and flexible dosing.

The addressable market size for the reference product is approximately US$1.5 billion. This partnership is positioned to address a significant unmet medical need, with Zydus leveraging its expertise to enhance therapy options in oncology. Investors should watch closely as this collaboration may yield substantial growth opportunities, tapping into a lucrative market segment and addressing critical patient needs.